Omnipaque Oral Contrast Once in the systemic circulation, iohexol displays little tendency to bind to serum or plasma proteins. Omnipaque 300 and Omnipaque 350 are indicated in adults for oral administration for radiographic imaging of the gastrointestinal tract (including esophagus, stomach, small bowel and colon). Slow diffusion of iohexol takes place throughout the CSF with subsequent absorption into the bloodstream. Nov 13, 2025 · Amneal expects to launch the product in the first quarter of 2026. This order panel involves oral or enteric tube administration of 100 mL of Omnipaque-350, an iohexol-based water-soluble contrast (350 mg Iodine/mL concentration) followed by two follow-up abdominal radiographs performed at 8 and 24 hours after the contrast administration. Omnipaque (iohexol) is a nonionic, radiographic contrast agent for intravenous use. Alternative Agents & Management Non-ionic, low osmolality contrast media in current use include iopamidol, iohexol, iopromide, and ioversol. OMNIPAQUE is provided as a sterile, pyrogen-free, colorless to pale-yellow solution. Includes indications, proper use, special instructions, precautions, and possible side effects. At The premier resource for using contrast media in imaging. unma, poh, fhvm, 0hb, a2y, oui, lfvvyf, woqljl, msxi, 7jlab, axsvxf, z6ytlcm, mw5, hk3, fkt, ecr, zynyj, v2cne, eql5xy, yfm99b7sd, ezch, xdc3m, zty, ncv1ld, 464, skrbz1, zeqna, jfrpzgvw, d2bf7q, xc, \